Skip to main content
| Hans-Günter Meyer-Thompson | Covid-19

Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies. 

Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies. 

Wüsthoff LEC, Lund-Johansen F, Henriksen K, Wildendahl G, Jacobsen JA, Gomes L, Anjum HS, Barlinn R, Kran AB, Munthe LA, Vaage JT. 

Harm Reduct J. 2024 Jun 19;21(1):120. doi: 10.1186/s12954-024-01023-9. PMID: 38890611; PMCID: PMC11186241.

Conclusions

Results showed that PWUD did not have increased serological responses to seasonal coronavirus and therefore no evidence of increased pre-existing immunity. The low prevalence of positive SARS-CoV-2 cases among PWUD was probably the result of a combination of the comprehensive general and the tailored mitigating strategies that were employed. Vaccine responses and coverage were not different from controls demonstrating that vaccination is a viable strategy to confer protection against SARS-CoV-2 in PWUD.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186241/